Imeroprubart

Monoclonal antibody

Also known as IMVT-1402

Phase 3underway

Evidence outlook · registrational

Myasthenia Gravis: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-12.

Also in development:Rheumatoid Arthritis · Phase 2Graves' Disease · Phase 2Chronic Inflammatory Demyelinating Polyneuropathy · Phase 2Sjögren's Disease · Phase 2

Development in Cutaneous Lupus Erythematosus stopped (2026-09-23) after a negative readout. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Myasthenia Gravis
Phase 2 (7)
Chronic Inflammatory Demyelinating Polyneuropathy
Graves' Disease
NCT07286006 · Immunovant Sciences GmbH
2026-01-26 – 2030-03 · Graves' Disease
What this study did
Rheumatoid Arthritis
Sjögren's Disease
Other / comorbidity
NCT06980805 · Immunovant Sciences GmbH
2025-02-19 – 2027-04 · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Chronic Inflammatory Demyelinating Polyneuropathy: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Imeroprubart: this drugPhase 2Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
Efgartigimod Alfa (Vyvgart)
Approved(overall)
Antibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
Efgartigimod Alfa And Hyaluronidase (Vyvgart Hytrulo)ApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
RiliprubartPhase 3Monoclonal antibodyComplement C1snot yet gradedNo reviewed efficacy summary in this indication
TAK-411
—(overall)
Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Imeroprubart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
May 2027 (1)
Phase 2Graves' DiseaseRecruiting
Est. primary completion 2027-05 · NCT07018323 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Rheumatoid ArthritisActive not recruiting
Est. primary completion 2027-09 · NCT06754462 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3Myasthenia GravisRecruiting
Est. primary completion 2027-12 · NCT07039916 · CT.gov ↗
What to watch
2028 (3)
June 2028 (1)
Phase 2Graves' DiseaseRecruiting
Est. primary completion 2028-06 · NCT06727604 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Sjögren's DiseaseActive not recruiting
Est. primary completion 2028-07 · NCT06979531 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Chronic Inflammatory Demyelinating PolyneuropathyRecruiting
Est. primary completion 2028-08 · NCT07032662 · CT.gov ↗
What to watch
2030 (1)
March 2030 (1)
Phase 2Graves' DiseaseEnrolling by invitation
Est. primary completion 2030-03 · NCT07286006 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

November 2026Topline resultRandomized withdrawal period (Period 2) in difficult-to-treat RA met its primary endpoint

Recent

23 September 2026Topline resultIMVT-1402 CLE proof-of-concept study misses primary endpoint; CLE development stopped
Immunovant, Inc. · Source ↗